| Dir : /home/ithome/mail/new/ |
| Server: Linux host100322.itwesthosting.com 3.10.0-1160.144.1.el7.tuxcare.els4.x86_64 #1 SMP Tue Apr 7 08:40:40 UTC 2026 x86_64 IP: 144.91.64.173 |
| Dir : /home/ithome/mail/new/1773814330.M930795P877.host100322.itwesthosting.com,S=7011,W=7147 |
Return-Path: <pharpharmacol@scienlist.com>
Delivered-To: ithome@host100322.itwesthosting.com
Received: from host100322.itwesthosting.com
by host100322.itwesthosting.com with LMTP
id OONSNzpCumltAwAAp0YrwQ
(envelope-from <pharpharmacol@scienlist.com>)
for <ithome@host100322.itwesthosting.com>; Wed, 18 Mar 2026 07:12:10 +0100
Return-path: <pharpharmacol@scienlist.com>
Envelope-to: senka.rendulic@bolnica-lipik.hr
Delivery-date: Wed, 18 Mar 2026 07:12:10 +0100
Received: from smtp.scienlist.com ([213.199.48.44]:60384)
by host100322.itwesthosting.com with esmtps (TLS1.2) tls TLS_ECDHE_RSA_WITH_AES_256_GCM_SHA384
(Exim 4.96.2)
(envelope-from <pharpharmacol@scienlist.com>)
id 1w2k8X-0000HM-1t
for senka.rendulic@bolnica-lipik.hr;
Wed, 18 Mar 2026 07:12:10 +0100
Received: from [127.0.0.1] (localhost [127.0.0.1]) by localhost (Mailerdaemon) with ESMTPSA id AB6FBCFA95
for <senka.rendulic@bolnica-lipik.hr>; Wed, 18 Mar 2026 15:12:08 +0900 (JST)
DKIM-Signature: v=1; a=rsa-sha256; c=relaxed/relaxed; d=scienlist.com;
s=dkim; t=1773814328;
h=from:reply-to:subject:date:message-id:to:mime-version:content-type;
bh=Zevq9oy42B59Ht3UbW0d0TMWRY+vcqXMnYjZhAHp9aA=;
b=cSq9XbsusCbtHBTqMJNXfghItjk7vm4dthBsJP6Z0/X+JDFVk0y4ulbUTlciOcyYeL3rOP
DYN2rQ6auRXOylmEmEMYFALpNqeFEqNyy2voQANW60O8RVIzyq3tArYSao4oAZQwI0RszV
ikwsXLL4TyPg1dMzNR3aMq07YYx4w1ozdc2z4yxbJcWPMGaGBVhpaIRnUH3OWMvSntEn+2
bWf9BPalUmu0YuBSflAg0O4H4FQi5uQjtQfHphUwow+QB/ANNgP9om9A8PuVG/yo1wk72X
+l1GdcfTEJqYNgTg/UYJZPnl2LPyWRPVOTMb5JEBmqgkeSWYMqhCD0+l5YdoYw==
Date: Wed, 18 Mar 2026 06:12:08 +0000
To: senka.rendulic@bolnica-lipik.hr
From: David Marks <pharpharmacol@scienlist.com>
Reply-To: david.marks@fortunejournals.com
Subject: Re: {{subject}}
Message-ID: <r6lM380meDDAZfxlNHz0bM3ZyBlfXHBqydNnypyk@vmi2959108>
MIME-Version: 1.0
Content-Type: multipart/alternative;
boundary="b1=_r6lM380meDDAZfxlNHz0bM3ZyBlfXHBqydNnypyk"
X-Last-TLS-Session-Version: TLSv1.3
X-Spam-Status: No, score=-0.2
X-Spam-Score: -1
X-Spam-Bar: /
X-Ham-Report: Spam detection software, running on the system "host100322.itwesthosting.com",
has NOT identified this incoming email as spam. The original
message has been attached to this so you can view it or label
similar future email. If you have any questions, see
root\@localhost for details.
Content preview: Hi,Season's greetings.We recently had the opportunity to read
your published article " Disease Activity, Inflammation Ma " and found it
to be a well-structured and scientifically meaningful contributi [...]
Content analysis details: (-0.2 points, 5.0 required)
pts rule name description
---- ---------------------- --------------------------------------------------
0.0 URIBL_BLOCKED ADMINISTRATOR NOTICE: The query to URIBL was
blocked. See
http://wiki.apache.org/spamassassin/DnsBlocklists#dnsbl-block
for more information.
[URIs: research.in]
-0.0 SPF_PASS SPF: sender matches SPF record
0.0 RCVD_IN_VALIDITY_RPBL_BLOCKED RBL: ADMINISTRATOR NOTICE: The
query to Validity was blocked. See
https://knowledge.validity.com/hc/en-us/articles/20961730681243
for more information.
[213.199.48.44 listed in bl.score.senderscore.com]
0.0 HTML_MESSAGE BODY: HTML included in message
-0.1 DKIM_VALID Message has at least one valid DKIM or DK signature
-0.1 DKIM_VALID_EF Message has a valid DKIM or DK signature from
envelope-from domain
0.1 DKIM_SIGNED Message has a DKIM or DK signature, not necessarily
valid
-0.1 DKIM_VALID_AU Message has a valid DKIM or DK signature from
author's domain
0.0 RCVD_IN_VALIDITY_CERTIFIED_BLOCKED RBL: ADMINISTRATOR NOTICE:
The query to Validity was blocked. See
https://knowledge.validity.com/hc/en-us/articles/20961730681243
for more information.
[213.199.48.44 listed in sa-accredit.habeas.com]
X-Spam-Flag: NO
X-From-Rewrite: unmodified, forwarded message
--b1=_r6lM380meDDAZfxlNHz0bM3ZyBlfXHBqydNnypyk
Content-Type: text/plain; charset=UTF-8
Content-Transfer-Encoding: quoted-printable
Hi,Season's greetings.We recently had the opportunity to read your publishe=
d article " Disease Activity, Inflammation Ma " and found it to be a well-s=
tructured and scientifically meaningful contribution. The scope and depth o=
f your study align closely with the focus of the Journal of Pharmacy and Ph=
armacology Research.In light of your expertise, I would like to invite you =
to consider submitting a new or related manuscript.The journal is indexed i=
n PubMed/PMC and holds an Impact Factor of 3.3. Our editorial process empha=
sizes constructive peer review and timely decisions, with the goal of suppo=
rting authors while maintaining high scientific standards.Should you wish t=
o explore this opportunity, I would be glad to provide further details rega=
rding submission and review.Thank you for your time, and I look forward to =
your response.
Kind regards,
David Marks
--b1=_r6lM380meDDAZfxlNHz0bM3ZyBlfXHBqydNnypyk
Content-Type: text/html; charset=UTF-8
Content-Transfer-Encoding: quoted-printable
<p data-start=3D"58" data-end=3D"81">Hi,</p><p data-start=3D"83" data-end=
=3D"104">Season's greetings.</p><p data-start=3D"106" data-end=3D"380">We r=
ecently had the opportunity to read your published article " <b>Disease Act=
ivity, Inflammation Ma</b> " and found it to be a well-structured and scien=
tifically meaningful contribution. The scope and depth of your study align =
closely with the focus of the <em data-start=3D"330" data-end=3D"377"><b>Jo=
urnal of Pharmacy and Pharmacology Research</b></em>.</p><p data-start=3D"3=
82" data-end=3D"589">In light of your expertise, I would like to invite you=
to <b>consider submitting a new or related manuscript.</b></p><p data-star=
t=3D"591" data-end=3D"825">The journal is indexed in <b>PubMed/PMC and hold=
s an Impact Factor of 3.3</b>. Our editorial process emphasizes constructiv=
e peer review and timely decisions, with the goal of supporting authors whi=
le maintaining high scientific standards.</p><p data-start=3D"827" data-end=
=3D"949">Should you wish to explore this opportunity, I would be glad to pr=
ovide further details regarding submission and review.</p><p data-start=3D"=
951" data-end=3D"1014">Thank you for your time, and I look forward to your =
response.</p><p class=3D"isSelectedEnd">
</p><p data-start=3D"1016" data-end=3D"1113" data-is-last-node=3D"" data-is=
-only-node=3D"">Kind regards,<br data-start=3D"1029" data-end=3D"1032">
David Marks</p>
--b1=_r6lM380meDDAZfxlNHz0bM3ZyBlfXHBqydNnypyk--